
The first NTR-responsive PROTAC, incorporating the caging group on the Von Hippel-Lindau (VHL) E3 ubiquitin ligase лиганд, efficiently degrading the EGFR protein and subsequently exert antitumor efficacy
The first NTR-responsive PROTAC, incorporating the caging group on the Von Hippel-Lindau (VHL) E3 ubiquitin ligase ligand, efficiently degrading the EGFR protein and subsequently exert antitumor efficacy
Только для научно-исследовательского применения. Не предназначено для использования у пациентов или в качестве лекарственного средства.